Skip to main navigation Skip to search Skip to main content

Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: A case of successful switch to an alternative ALK inhibitor and systematic review of the literature

Research output: Contribution to journal › Article › peer-review

Abstract

Alectinib can cause rare, but severe hypersensitivity. The cross-reactivity between different ALK inhibitors is unknown and desensitization is the only reported management. We hereby report the first case of severe delayed hypersensitivity developed in a lung cancer patient treated by alectinib, who was successfully managed by switching to brigatinib, another ALK inhibitor. The patient achieved excellent anti-tumor response to brigatinib. Our case provides an alternative and safe strategy in patients with alectinib-related hypersensitivity.

Original languageEnglish (US)
Pages (from-to)73-77
Number of pages5
JournalLung Cancer: Targets and Therapy
Volume9
DOIs
StatePublished - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Alectinib
  • Brigatinib

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: A case of successful switch to an alternative ALK inhibitor and systematic review of the literature'. Together they form a unique fingerprint.

Cite this